Perlegen in pharmacogenomics deals with Johnson & Johnson and AstraZeneca
This article was originally published in Clinica
Johnson & Johnson and AstraZeneca have signed separate pharmacogenomics agreements with genomics firm Perlegen Sciences. Under the agreements, Perlegen's single nucleotide polymorphisms (SNPs) technology will be used to find genetic markers for patients' response to drug agents made by both partners.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.